Rhesus IFNA2 / Interferon alpha 2 Protein

Catalog Number: **90105-CNAY**

Sino Biological
Biological Solution Specialist

General Information

Gene Name Synonym:

IFNA2

Protein Construction:

A DNA sequence encoding the rhesus IFNA2 (NP_001129266.1) (Cys24-Glu188) was expressed.

Source: Rhesus

Expression Host: Yeast

QC Testing

Purity: ≥ 80 % as determined by SDS-PAGE

Bio Activity:

Measured in antiviral assay using WISH cells infected with vesicµLar stomatitis virus. The ED_{50} for this effect is typically 1.8-7.4 pg/mL.

Endotoxin:

Please contact us for more information.

Predicted N terminal: Cys 24

Molecular Mass:

The recombinant rhesus IFNA2 consists 165 amino acids and predicts a molecular mass of 19.5 kDa.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Stability & Storage:
Samples are stable for twelve months from date of receipt at -20℃ to -80℃.

Store it under sterile conditions at -20℃ to -80℃ upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

Type I Interferons (IFNs) are well known cytokines which exert antiviral activity, antitumor activity and immunomodulatory effects. Interferon tau (IFNT), a type I IFN similar to alpha IFNs (IFNA), is the pregnancy recognition signal produced by the ruminant conceptus. Among IFN-α genes, a total of 28 different sequence variants have been described.The three principal subtypes of IFNα-2 are designated α-2a, α-2b, and α-2c. IFNα-2b is being the predominant allele while IFNα-2a is less predominant and IFNα-2c only a minor allelic variant.

References

1.Wang, et al. (2004) Fever of recombinant human interferon-alpha is mediated by opioid domain interaction with opioid receptor inducing prostaglandin E2. J Neuroimmunol. 156(1-2): 107-12.
2.Groopman JE, et al. (1984) Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med. 100(5): 671-6.
3.Krueger JM, et al. (1987) Interferon alpha-2 enhances slow-wave sleep in rabbits. Int J Immunopharmacol. 9(1): 23-30.